Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oncopeptides AB (publ)
  6. News
  7. Most relevant
    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ONCOPEPTIDES AB (PUBL)
01/21ONCOPEPTIDES : Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto
PU
01/21Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market i..
AQ
01/21Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Mar..
CI
01/13Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
AQ
01/13Oncopeptides AB Announces Data from Phase 3 Ocean Study Published in the Lancet Haemato..
CI
01/05Oncopeptides announces year-end cash 2021
AQ
2021Multiple Myeloma Hub continues to provide the latest treatment and research updates in ..
AQ
2021Oncopeptides presents new melflufen data at the Annual American Society of Hematology M..
AQ
2021Oncopeptides publishes Q3 2021 report
AQ
2021Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
2021ONCOPEPTIDES : Webcast - Presentation of the Q3 Interim Report 2021
PU
2021Invitation to presentation of the Q3 2021 results
AQ
2021Oncopeptides Jumps 39% as New CEO Takes Over
MT
2021Jakob Lindberg appointed CEO of Oncopeptides
AQ
2021Oncopeptides AB Announces Changes in CEO
CI
2021Oncopeptides has announced the Nomination Committee
AQ
2021Oncopeptides AB announces appointment of the Nomination Committee
CI
2021Oncopeptides Stops Certain Clinical Studies of Blood Cancer Drug
MT
2021Oncopeptides focuses clinical development efforts to increase cash runway
AQ
2021Oncopeptides Names Interim CFO
MT
2021Oncopeptides appoints Annika Muskantor as interim CFO
AQ
2021Oncopeptides AB Announces Executive Changes
CI
2021ONCOPEPTIDES : Plunges 33% on Decision to Withdraw from US Market
MT
2021Oncopeptides Withdraws Pepaxto? in US, Scale Down Organization and Focus on R&D
CI
2021ONCOPEPTIDES : withdraws Pepaxto« in US, scale down organization and focus on R&D
PU
2021ONCOPEPTIDES : Webcast - Oncopeptides withdraw Pepaxto« in US, scale down organization and..
PU
2021ONCOPEPTIDES : withdraws Pepaxto«in US, scale down organization and focus on R&D
AQ
2021ONCOPEPTIDES : CFO to Leave
MT
2021ONCOPEPTIDES' : CFO Anders Martin-Löf will leave the company
AQ
2021Oncopeptides AB Announces Resignation of Anders Martin-Löf as CFO
CI
2021MAGLE CHEMOSWED : establishes a manufacturing agreement with Oncopeptides
AQ
2021ONCOPEPTIDES : Handelsbanken Healthy Hour - presentation
PU
2021ONCOPEPTIDES : Drug Combo Improves Survival in Blood Cancer Patients
MT
2021ONCOPEPTIDES : presents phase 3 OCEAN study results at the IMW meeting
AQ
2021Oncopeptides AB Presents Phase 3 Ocean Study Results At the IMW Meeting
CI
2021ONCOPEPTIDES : Webcast for presentation of OCEAN data presented at IMW
PU
2021ONCOPEPTIDES : Invitation to webcast for presentation of OCEAN data presented at IMW
AQ
2021Certain Shares of Oncopeptides AB are subject to a Lock-Up Agreement Ending on 9-SEP-20..
CI
2021ONCOPEPTIDES : Regulatory update from US Food and Drug Administration
AQ
2021Oncopeptides AB Announces Regulatory Update from US Food and Drug Administration
CI
2021ONCOPEPTIDES : presents new data from OCEAN and PORT study - abstracts online
AQ
2021Oncopeptides AB Presents New Data from OCEAN and PORT Study - Abstracts Online
CI
2021ONCOPEPTIDES : Financial Reporting Document
PU
2021ONCOPEPTIDES : publishes report for Q2 2021
AQ
2021Oncopeptides AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
2021Oncopeptides AB Announces Pepaxto« Receives A Permanent J-Code, Clarifying Reimbursemen..
CI
2021ONCOPEPTIDES : Presentation of the Q2 Interim Report 2021
PU
2021ONCOPEPTIDES : Invitation to presentation of the Q2 2021 results
AQ
2021Oncopeptides AB Announces US Food and Drug Administration Issues Safety Alert to Patien..
CI
2021ONCOPEPTIDES : Regulatory update from US Food and Drug Administration
AQ
2021FDA Flags Increased Death Risk in Studies of Oncopeptides Drug Pepaxto
DJ
2021Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further ..
CI
2021ONCOPEPTIDES : Tanks 24% As US FDA Calls For Partial Clinical Hold On Cancer Drug
MT
2021ONCOPEPTIDES : Updated results from phase 3 OCEAN study shows melflufen met primary endpoi..
AQ
2021Oncopeptides AB Updates Results from Phase 3 Ocean Study Shows Melflufen Met Primary En..
CI
2021ONCOPEPTIDES : Number of shares and votes in Oncopeptides
AQ
2021Certain Shares of Oncopeptides AB are subject to a Lock-Up Agreement Ending on 11-JUN-2..
CI
2021ONCOPEPTIDES : Redeye Growth Day 2021 presentation
PU
2021ONCOPEPTIDES : Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AQ
2021ONCOPEPTIDES : Presentation of the Q1 Interim Report 2021
PU
2021ONCOPEPTIDES : Financial Reporting Document
PU
2021ONCOPEPTIDES : publishes report for Q1 2021 and updated dates for the publication of the r..
AQ
2021Oncopeptides AB Publ Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
2021ONCOPEPTIDES : Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious ..
AQ
2021Oncopeptides AB Announces Phase 3 Ocean Study Demonstrates Melflufen Is At Least as Eff..
CI
2021Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean ..
CI
2021ONCOPEPTIDES : Invitation to presentation of the Q1 2021 results
AQ
2021Oncopeptides AB Presents Clinical Abstracts on Melflufen At the 2021 American Society o..
CI
2021ONCOPEPTIDES : presents clinical abstracts on melflufen at the 2021 American Society of Cl..
AQ
2021ONCOPEPTIDES : Says Interim Results Of Melflufen Study Support Use In Moderate Renal Impai..
MT
2021Oncopeptides AB Presents New Clinical and Preclinical Melflufen Data at the Upcoming Eu..
CI
2021ONCOPEPTIDES : presents new clinical and preclinical melflufen data at the upcoming Europe..
AQ
2021ONCOPEPTIDES : Aktiedagen Stockholm - Aktiespararna
PU
2021ONCOPEPTIDES : completes patient enrollment in phase 2 PORT study
AQ
2021Oncopeptides AB Completes Patient Enrollment in Phase 2 Port Study
CI
1  2  3  4Next
Upcoming event on ONCOPEPTIDES AB (PUBL)